Literature DB >> 32668998

Statin use and safety concerns: an overview of the past, present, and the future.

Rubina Mulchandani1,2, Tanica Lyngdoh1, Ashish Kumar Kakkar3.   

Abstract

INTRODUCTION: Dyslipidemia is a significant risk factor for cardiovascular disorders and contributes to significant morbidity and mortality associated with CAD and stroke worldwide. Statins are the most commonly prescribed drugs for the prevention and management of dyslipidemia globally. Although they provide immense therapeutic benefit, they are associated with clinically significant adverse effects, predominantly muscle, nerve, liver, and cognition-related besides new-onset diabetes. This has sparked various controversies, bringing to the fore, ambiguities that continue to exist in the scientific evidence, in relation to statin-associated harms. Therefore, it becomes essential to have a better understanding of safety issues related to statin use in various populations. AREAS COVERED: This review describes the most common adverse effects of statins, examines available evidence and highlights the role of ethnicity, lipophilicity and other biological factors that could mediate and/or influence the relationship. MEDLINE was searched via PubMed to obtain relevant articles on dyslipidemia and statin safety. EXPERT OPINION: The effectiveness of statins is presently unmatched. Further research is warranted to gain insights into the diverse pharmacological effects of statins in various population subgroups. This would assist prescribers in making better informed decisions. Specific treatment strategies for vulnerable groups can significantly attenuate harms, improve risk-benefit ratios, and ultimately enhance patient experience.

Entities:  

Keywords:  Statins; cognitive adverse effects; coronary artery disease; drug safety; muscle-related adverse events

Mesh:

Substances:

Year:  2020        PMID: 32668998     DOI: 10.1080/14740338.2020.1796966

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  2 in total

1.  Simvastatin accelerated motoneurons death in SOD1G93A mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles.

Authors:  Lin Bai; Yafei Wang; Jia Huo; Shuai Li; Ya Wen; Qi Liu; Jing Yang; Yaling Liu; Rui Li
Journal:  Cell Death Dis       Date:  2021-04-12       Impact factor: 8.469

2.  Effect of statins on risk and mortality of urologic malignancies: Protocol of an umbrella review.

Authors:  Xinyu Zhai; Pengsheng Yi; Xitao Wang; Haifeng Wang; Xuejun Yang; Zubing Mei; Minyao Ge
Journal:  PLoS One       Date:  2022-03-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.